Pfizer's Covid-19 Drug is almost 90% Effective
Pfizer's Cvid-19 drug is almost 90% effective in preventing hospitalization or death in high-risk patients, according to a recent study by the world's news agencies.
The results were announced by the manufacturer. Pfizer also said that laboratory tests suggested that the pill also worked against the rapidly spreading Omicron variant of the coronavirus.
The US company said last month that the drug was about 89% effective in preventing hospitalization or death when compared to a placebo in nearly 1,200 volunteers.
Another 1,000 people took part in the new study, which was presented today.
None of the volunteers treated with Pfizer died, and there were twelve deaths in the placebo group.
The company's medicine was taken in combination with the antiviral drug ritonavir every 12 hours for five days, starting shortly after the onset of symptoms of Covid-19.
If approved, the medicine will be sold as Paxlovid.
Pfizer also presented initial data from a second clinical trial, which showed that treatment with Covid-19 reduced hospitalizations by about 70% in nearly 600 adults at standard risk.
"This is a stunning result," said Mikael Dolsten, the company's chief scientific officer. He explained that he expects soon approval from the US Food and Drug Administration for the use of the drug in high-risk patients.
There is currently no approved oral antiviral treatment for the new coronavirus in the country.
Merck has requested authorization for its experimental drug against Covid-19 molnupiravir. According to studies, it reduces the risk of hospitalization or death by 30%.
/BTA
We need your support so Novinite.com can keep delivering news and information about Bulgaria! Thank you!
Bulgaria's Cardiovascular Crisis: Deputy PM Urges Action
Bulgaria is grappling with a staggering burden of cardiovascular diseases, with more than 6 million new cases and over 1.8 million deaths reported annually
Japan Faces Surge in Deadly Strep Throat Infections: Warning Issued
Japanese health authorities have issued a warning as the nation grapples with a significant uptick in potentially fatal strep throat infections, particularly in Tokyo
New WHO/Europe Study Reveals One in Six School-Aged Children Experience Cyberbullying
The World Health Organization (WHO) Regional Office for Europe today released the second volume of the Health Behaviour in School-aged Children (HBSC) study, which focuses on patterns of bullying and peer violence among adolescents across 44 countries and
WHO: Ahead of us lies a future free of TB
Statement on World TB Day by WHO Regional Director for Europe, Dr Hans Henri P. Kluge
Bulgaria's Ministry of Finance: 56 Heart Disease Medicines to Be Free Starting April
The Ministry of Finance has disclosed its affirmative stance on allocating resources for covering the entire cost of 56 drugs targeting cardiovascular diseases, such as those addressing hypertension, arrhythmia, and other frequently occurring chronic ailm
Sleep Struggles: Over 70% of Bulgarians Face Insomnia Challenges
During World Sleep Day week, data from recent studies conducted by the Pragmatica Agency and iSleep show that more than 70% of Bulgarians struggle to initiate sleep and experience nighttime awakenings